top of page

Inflection Biosciences Appoints John Lynch to its Board of Directors

Dublin, Ireland, March 16, 2015

Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced the appointment of John Lynch to its Board as a non-executive director.

John Lynch has extensive pharmaceutical industry experience, with a 25 year career of achievement in many facets of the industry. His experience covers strategy development, business development, investor relations, product development, sales & marketing and finance.

John served as CEO at Merrion Pharmaceuticals plc, successfully raising funds and completing partnership deals with several pharmaceutical companies. He held senior roles at Abbott Laboratories in the USA, UK and Ireland spanning a 15 year period. As well as public and private company boards, he has served on state boards, university boards and on the Irish Government’s Innovation Taskforce.

Darren Cunningham, Chief Executive Officer of Inflection Biosciences, commented, ‘We are very pleased that John has joined the Board. John’s leadership at Merrion Pharmaceuticals plc, and his international commercial roles in such companies as Abbott Laboratories will bring invaluable experience and knowledge to the Company.’

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit


bottom of page